Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
Levonorgestrel-piroxicam Combination Versus Ulipristal Acetate for Emergency Contraception: a Randomised Double-blind Controlled Trial
The University of Hong Kong
980 participants
Jan 18, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to compare the failure rate of the levonorgestrel (LNG)-piroxicam combination regimen versus ulipristal acetate (UPA) as emergency contraception (EC). The main questions it aims to answer are: 1. whether the LNG-piroxicam combination regimen has a lower failure rate than UPA for EC; 2. whether the LNG-piroxicam combination regimen has a higher percentage of pregnancies prevented than UPA for EC 3. whether there is any difference in the change in the subsequent menstrual cycle and adverse effect profile between the two regimens Participants will: 1. Take a single dose of either (i) LNG 1.5 mg plus piroxicam 40 mg and a placebo tablet resembling UPA, or (ii) UPA 30 mg plus placebo tablets resembling LNG and piroxicam. 2. Have a blood test for serum LH, oestradiol an progesterone. 3. Keep a diary of their vaginal bleeding episodes, adverse effects symptoms, any further acts of intercourse and the type of contraception used. 4. Have a follow-up either in person by phone about 1-2 weeks after the next expected menstruation. 5. If normal menstrual bleeding has not occurred by that time, a pregnancy test will be carried out.
Eligibility
Inclusion Criteria3
- women aged 18-45 years;
- requesting an oral EC within 120 hours of a single or the first act of unprotected intercourse in the current menstrual cycle;
- available for follow-up over the next 6 weeks.
Exclusion Criteria11
- post-abortion or postpartum and period have not yet returned,
- being on the following drugs currently: anticoagulants, cyclosporine, tacrolimus, corticosteroids, lithium, serotonin reuptake inhibitors (SSRIs), quinolones
- having unprotected intercourse in this cycle more than 120 hours before attending the clinic,
- being found pregnant at the time of presentation,
- breastfeeding,
- having been sterilized (or partner having been sterilized) or having intrauterine contraceptive device in-situ,
- uncertain about the date of the last menstrual period,
- having used a hormonal contraceptive (including EC), progestogen-containing medication or NSAID in the recent one week,
- having history of asthma, urticaria or other allergic reactions to piroxicam, aspirin or other NSAIDs,
- having history of ischaemic heart disease, heart failure, hypertension, cerebrovascular disease or kidney failure requiring dialysis
- having history of peptic ulcer disease and/or gastrointestinal bleeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Levonorgestrel 1.5 mg
Piroxicam 40 mg
Ulipristal 30 mg
Placebo of levonorgestrel
Placebo of piroxicam
Placebo of ulipristal acetate
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06727734